Chromoendoscopy Agents Market: Introduction According to the report, the global chromoendoscopy agents market was valued over US$ 100 Mn in 2020 and is projected to expand at a CAGR of ~3% from 2021 to 2031. Chromoendoscopy, particularly in combination with magnifying endoscopy, has helped healthcare professionals in the detection of neoplastic lesions in the gastrointestinal mucosa, specifically in ulcerative colitis and Crohn’s colitis. Chromoendoscopy is helpful in the upper gastrointestinal tract, primarily in evaluating Barrett’s oesophagus (BO) for the presence of dysplasia. It also improves visualization and detection of suspicious lesions, and helps to define the extent of neoplastic lesions that may be responsive to endoscopic resection. Such advantages associated with chromoendoscopy over conventional white light endoscopy are expected to contribute to market growth. The global population is aging rapidly. According to the WHO, nearly 2 billion people are expected to be aged 60 and above by 2050, which is around 16.7% of the global population. Incidence and prevalence of gastrointestinal diseases (GI), such as colorectal and pancreatic cancers, inflammatory bowels disease, and gastroesophageal reflux disease (GERD), increase with age. Several of these conditions can be diagnosed or cured by using endoscopy procedures. Hence, increase in geriatric population and surge in incidence of diseases are expected to boost the demand for chromoendoscopy agents. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=37196 Moreover, favorable medical reimbursement policies for different endoscopy procedures in developed countries such as the U.S., Australia, New Zealand, the U.K., and Germany have enabled most people affected with gastrointestinal diseases to opt for effective endoscopic procedure. These reimbursement policies have driven the revenue of leading players in the international market. The chromoendoscopy agents market in Asia Pacific is expected to expand at a CAGR of 4% from 2021 to 2031. Robust economic development, high gastrointestinal disease burden, and developing healthcare sector are anticipated to drive the market in Asia Pacific. Increase in Incidence of Gastrointestinal Diseases to Drive Global Market The incidence and prevalence of gastrointestinal (GI) diseases across the world are increasing at a high rate affecting millions of people. According to Acid Reflux (GERD) Statistics and Facts, 60% of adults develop GERD within a year, and up to 30% have symptoms on a weekly basis. GERD affects around 7 million people in the U.S. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), GERD affects 20% of the population of the U.S. The incidence of GERD is high in countries in North America, Australia/Oceania, and Northern Europe, while incidence is moderate in Western & Southern Asia and South America. Eastern Asia and Southern Europe have low incidence of GERD. According to the Global Cancer Statistics, over 1.9 million new colorectal cancer (including anus) cases and 935,000 deaths were recorded in 2020, accounting for around one in every 10 cancer cases and deaths. Colorectal cancer is the third most common cancer in the U.S., but it is the second in terms of mortality. Chromoendoscopy agents are used in visualization and detection of dysplastic and malignant lesions in the gastrointestinal tract, which can be difficult to distinguish from normal mucosa. Therefore, increase
Chromoendoscopy Agents Market Key Opportunities and Forecast up to 2031
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.